



Press release
For immediate release

VICTHOM HUMAN BIONICS INC. FILES FIRST DEFAULT STATUS REPORT

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Quebec (Canada), April 15, 2009 – Victhom Human Bionics Inc. (“Victhom”) (TSX: VHB)) is providing its first biweekly Default Status Report under National Policy 12-203 - *Cease Trade Orders for Continuous Disclosure Defaults* (“NP 12-203”). On April 1, 2009, Victhom announced that its audited annual financial statements, CEO and CFO certification, management discussion and analysis (“MD&A”) and annual information form (“AIF”) for the year ended December 31, 2008 would not be released as required by March 31, 2009.

In accordance with NP 12-203 and as previously announced, Victhom has voluntarily requested that the *Autorité des marchés financiers* and other Canadian securities regulatory authorities issue a temporary order that prohibits certain directors, officers and insiders of Victhom from trading in securities of Victhom for as long as the annual financial statements, CEO and CFO certifications and related MD&A and AIF are not filed (the “Management Cease Trade Order”).

Discussions are still ongoing with the objective to complete, in the short term, a transaction to allow Victhom to continue its research and development activities. Victhom still anticipates that the release of the annual financial statements, CEO and CFO certifications and related MD&A and AIF will occur no later than April 30, 2009.

Victhom reports that since announcing the Management Cease Order of April 1, 2009, there have not been any material changes to the information contained therein; nor any failure by Victhom to fulfill its intentions as stated therein with respect to satisfying the provisions of the alternative information guidelines, and there are no additional defaults or anticipated defaults subsequent to such announcement. Further, there have been no additional material changes respecting Victhom and its affairs. Victhom intends to file, if required, its next Default Status Report by April 29, 2009.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom’s Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom’s Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

- 30 -

For more information:**Victhom Human Bionics Inc.**

Normand Rivard

Acting President and Chief Financial Officer

Victhom Human Bionics Inc.

Tel.: 418-872-5665

Fax: 418-864-7034

normand.rivard@victhom.com

www.victhom.com